Clinical Trial Update: Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping [Phase 2]

View source ↗

Summary

Phase 2 trial exploring brigatinib in ALK-positive non-small cell lung cancer with deep phenotyping.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alunbrig (Brigatinib)

Snippet

Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Conditions: NSCLC | Phase 2 | Status: ACTIVE_NOT_RECRUITING